Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunmax Biotechnology CoROCO:4728 -0.52%87 ROC (Joel Greenblatt) % is 132.92% as of Mar. 2026, which is 22% above its 10-year median of 109.34. GuruFocus rates ROCO:4728 with a GF Score™ of 87/100 and a GF Value™ of NT$344.11 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,324 Biotechnology companies, Sunmax Biotechnology Co ranks better than 94.94% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sunmax Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 132.92%.
The historical rank and industry rank for Sunmax Biotechnology Co's ROC (Joel Greenblatt) % or its related term are showing as below:
ROCO:4728'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.65 Med: 109.34 Max: 486.17
Current: 110.23
During the past 13 years, Sunmax Biotechnology Co's highest ROC (Joel Greenblatt) % was 486.17%. The lowest was 4.65%. And the median was 109.34%.
ROCO:4728's ROC (Joel Greenblatt) % is ranked better than 94.94% of 1324
companies
in the Biotechnology industry
Industry Median: -291.75
vs ROCO:4728: 110.23
Sunmax Biotechnology Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -4.20% per year.
Sunmax Biotechnology Co (ROCO:4728) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Sunmax Biotechnology Co ROC (Joel Greenblatt) % Related Terms
Sunmax Biotechnology Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sunmax Biotechnology Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunmax Biotechnology Co ROC (Joel Greenblatt) % Chart
ROCO:4728 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Sunmax Biotechnology Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunmax Biotechnology Co ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunmax Biotechnology Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sunmax Biotechnology Co's ROC (Joel Greenblatt) % falls into.
Sunmax Biotechnology Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 132.92% mean?
Sunmax Biotechnology Co (ROCO:4728) has a ROC (Joel Greenblatt) % of 132.92% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sunmax Biotechnology Co and its competitors. This is 22% above median its historical median of 109.34. Over the past decade, Sunmax Biotechnology Co's ROC (Joel Greenblatt) % has ranged from 4.65 to 486.17. According to the industry distribution chart, Sunmax Biotechnology Co ranks #67 out of 1324 companies in the Biotechnology industry, placing it in the top 5.1%.
Is Sunmax Biotechnology Co's ROC (Joel Greenblatt) % too high?
Sunmax Biotechnology Co's current ROC (Joel Greenblatt) % of 132.92% is 22% above median its 10-year median of 109.34. Over the past 10 years, this metric has ranged from a low of 4.65 to a high of 486.17. Based on the distribution chart, Sunmax Biotechnology Co ranks #67 out of 1324 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sunmax Biotechnology Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sunmax Biotechnology Co's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunmax Biotechnology Co ranks #67 out of 1324 companies for ROC (Joel Greenblatt) %. This places Sunmax Biotechnology Co in the top 5% of its industry — outperforming the majority of peers. Historically, Sunmax Biotechnology Co's own ROC (Joel Greenblatt) % has ranged from 4.65 to 486.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sunmax Biotechnology Co and its competitors. Sunmax Biotechnology Co's current ROC (Joel Greenblatt) % is 132.92%, which is 22% above median its own 10-year median of 109.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunmax Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Sunmax Biotechnology Co (ROCO:4728) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$344.11, compared to a current price of NT$381.00 — trading 10.7% above its estimated fair value. The current ROC (Joel Greenblatt) % is 132.92%, which is 22% above median its 10-year median of 109.34. Sunmax Biotechnology Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sunmax Biotechnology Co (ROCO:4728), the current ROC (Joel Greenblatt) % is 132.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunmax Biotechnology Co (ROCO:4728) Overvalued in 2026?
Based on GuruFocus' analysis, Sunmax Biotechnology Co stock appears to be overvalued.
The current stock price of NT$381.00 is trading 10.7% above its estimated GF Value™ of NT$344.11.
GuruFocus considers Sunmax Biotechnology Co to be Modestly Overvalued.
Key valuation signals for ROCO:4728:
ROC (Joel Greenblatt) %: 132.92% (22% above median its 10-year median of 109.34)
GF Value™: NT$344.11 vs. price of NT$381.00 (10.7% above fair value)
No single metric tells the full story. See the ROCO:4728 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.
87GF Score
Get the complete analysis for ROCO:4728
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4728 has been successfully added to your 
